Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Temsirolimus as Second-line Therapy in HCC

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2012 by University of Tennessee Cancer Institute.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
University of Tennessee Cancer Institute
ClinicalTrials.gov Identifier:
NCT01567930
First received: February 1, 2012
Last updated: December 13, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2013
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)